Company Overview and News
Thor Industries, Inc. (THO - Free Report) reported fourth-quarter fiscal 2018 (ended Jul 31, 2018) adjusted earnings of $1.67 per share, missing the Zacks Consensus Estimate of $1.93. Moreover, adjusted earnings decreased roughly 26% from the year-ago figure of $2.26. Net income declined to $88.2 million from $119.5 million in the prior-year quarter. For fiscal 2018, adjusted earnings per share increased year over year from $7.
OSK THO PCAR
Genuine Parts Company (GPC - Free Report) announced that it is acquiring companies for its two groups. One of the acquisitions is for its Industrial Parts Group that operates under the name Motion Industries, while the other is for its U.S. Automotive Parts Group. Genuine Parts’ Motions Industries has signed an agreement to acquire Sunrise, FL-based Hydraulic Supply Company (“HSC”). Established in 1947, HSC is a leading distributor of hydraulic, pneumatic, and industrial components and systems.
The month of September is traditionally notorious in Wall Street for never providing positive returns. However, the first two weeks of the month this year has balanced the investor’s portfolio with negative and positive returns, with ensuing week already in the positive territory. Will September break the trend this year? While we await the answer, the three major stock market indexes – the Dow 30, S&P 500 and Nasdaq Composite – are at present within the striking distance to achieve their all-time high level.
CATR CAT AAPL NTAP PCAR LB ILMN
Those who screen for yields of 3% or more miss Paccar due to the annual special dividend.
Per Reuters, Johnson Controls International plc’s (JCI - Free Report) power solutions business will soon have two shortlisted bidders, as informed by banking sources. In order to back the company’s unit sales, these banks are working on a jumbo debt financing of more than $10 billion. The buyout of Johnson Control’s power solutions unit, which manufactures advanced batteries for vehicles, is expected to generate approximately $12 billion.
BAMGF MTSI MDPEB PCAR ALSN MDP JCI BAMKF APO BAM
AutoZone, Inc. (AZO - Free Report) has reported adjusted earnings of $18.54 per share in the fourth quarter of fiscal 2018 (ended Aug 25, 2018), beating the Zacks Consensus Estimate of $17.88. The figure was $15.27 in fourth-quarter fiscal 2017. For fiscal 2018, adjusted earnings per share increased year over year from $44.07 to $48.77. Revenues improved 1.3% year over year to $3.6 billion in the reported quarter and it was almost in line with the Zacks Consensus Estimate.
AZO MDPEB PCAR ALSN MDP
WABCO Holdings Inc. (WBC - Free Report) reported that it has inked multiple business deals and long-term agreement extensions with companies across Europe, the United States and Asia-Pacific. Valued at $660 million, these deals will enable the company to maintain its global leadership in offering braking control systems for trucks, buses and trailers. The business deals signed include various multiple braking system platforms offered by WABCO, comprising its award-winning modular braking system platform (mBSP).
WBC PCAR ALSN
Lithia Motors, Inc. (LAD - Free Report) has inked a strategic partnership with San Francisco-based e-commerce retailer, Shift. The underlying idea is to capture majority of used vehicles — above 40 million to be specific — sold in the United States per year and use more technology for simplifying the car buying and ownership experience. Such an alliance will allow both companies to collaborate with respect to technology, inventory, data, business and physical network.
FOXF PCAR LAD
Investors interested in Automotive - Domestic stocks are likely familiar with Paccar (PCAR - Free Report) and Fox Factory Holding (FOXF - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
FOXF CY PCAR
Chicago, IL –September 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Peugeot S.A. (PUGOY - Free Report) , CNH Industrial N.V. (CNHI - Free Report) , Honda Motor Co., Ltd. (HMC - Free Report) and PACCAR Inc (PCAR - Free Report) .
WFC WFCNP DB CY PCAR MBUU
In the recent past, major developments in additive manufacturing (AM) technology, better known as 3D printing, have transformed the ways in which products are designed and manufactured. Owing to the rising economic and environmental concerns, the paradigm shift in 3D printing technology, particularly over the past decade, has seen a phenomenal rise in popularity and adoption especially among capital-intensive industries.
The popularity of value investing is on the rise. The success of billionaire value investors like Warren Buffett further underscores the fact. Over the past five years, his conglomerate Berkshire Hathaway's book value has grown at a compound annual rate of 11% (The Economist). Per a July Motley Fool article last year, over the past 50 years, the stock has yielded a compound annual return of 20.8%. This indicates that an investment of $10,000 in 1965 would be worth $88 million today.
PK BRK.A CATR ARCB CAT CFX PCAR
CNH Industrial N.V.’s (CNHI - Free Report) brand IVECO BUS has signed a five-year agreement with Belgium’s Brussels public transport operator STIB-MIVB to deliver 141 Urbanway buses. Per the agreement, IVECO BUS will offer a package, including planning, construction, implementation, and supply of spare parts and battery pack maintenance along with traction chain components. By the end of 2019, these new buses will aid STIB-MIVB to increase Brussels bus network’s total capacity by almost one-third.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to PCAR / PACCAR, Inc. on message board site Silicon Investor.
|ZIP ZipCar Car Sharing Service||ZIP ZipCar Car Sharing Service||ZIP ZipCar Car Sharing Service|
as of ET